Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$41.12 USD
+0.14 (0.34%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $41.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.12 USD
+0.14 (0.34%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $41.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Zacks News
Mirum Pharma (MIRM) Stock Rises 42% Year to Date: Here's Why
by Zacks Equity Research
Mirum Pharma (MIRM) surges 42% year to date due to encouraging progress in label-expansion efforts of Livmarli, along with strategic initiatives, to expand its commercial portfolio.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -13.58% and 24.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 16.67% and 3.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of -17.65% and 3.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in IDEAYA Biosciences, Inc. (IDYA): Can Its 35.7% Jump Turn into More Strength?
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up
by Zacks Equity Research
Mirum Pharmaceuticals (MIRM) announces FDA approval of Livmarli for infants 3 months and older. Stock up 6% in response to the news.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -1.02% and 11.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Celularity (CELU) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on updates on Celularity's (CELU) pipeline candidates when it reports its fourth-quarter earnings.
Why Mirum Pharmaceuticals (MIRM) Might Surprise This Earnings Season
by Zacks Equity Research
Mirum Pharmaceuticals (MIRM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -46.15% and 1.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 2.86% and 11.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences (CHRS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -81.13% and 20.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of -40.74% and 13.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 20% and 11.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is MedAvail (MDVL) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how MedAvail Holdings, Inc. (MDVL) and Mirum Pharmaceuticals, Inc. (MIRM) have performed compared to their sector so far this year.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 15.83% and 48.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Mirum Pharmaceuticals (MIRM)
by Zacks Equity Research
Mirum Pharmaceuticals (MIRM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 4.91% and 0.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan
by Zacks Equity Research
Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.